Amaranth Medical Announces Investment from Boston Scientific

By: Benzinga
Amaranth Medical today announced the closing of an equity investment by Boston Scientific Corporation (NYSE: BSX ). The additional investment capital will be used to advance the clinical development of the Amaranth FORTITUDE™ drug eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE Mark. In addition, the funding will support
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.